Next 10 |
home / stock / verv / verv articles
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite the stock’s p...
Pipeline and regulatory updates continue to be in focus in the biotech sector. While nothing much came out of bigwigs apart from a few, shares of c...
Investors can contact the law firm at no cost to learn more about recovering their losses ?LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down 1.07% to 39,142.53 wh...
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. Stryve Foods post...
Verve Therapeutics Inc (NASDAQ:VERV) announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in pa...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 ...
LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investi...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional informat...
2024-04-06 09:50:00 ET Verve Therapeutics (NASDAQ: VERV) saw its shares crater by 36% on April 2 when it reported that a serious mishap had occurred in one of its clinical trials. Understandably, investors may now question whether the gene-editing biotech has a shot at recovering, o...